NCT00652743View on ClinicalTrials.gov

Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

PHASE3CompletedINTERVENTIONAL
Enrollment

845

Participants

Timeline

Start Date

March 23, 2008

Primary Completion Date

June 8, 2011

Study Completion Date

June 8, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemic influenza vaccine GSK1562902A

IM administration

Trial Locations (6)

100

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

10700

GSK Investigational Site, Bangkok

308433

GSK Investigational Site, Singapore

529889

GSK Investigational Site, Singapore

Unknown

GSK Investigational Site, Hong Kong

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00652743 - Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules | Biotech Hunter | Biotech Hunter